Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment

Chronic myeloid leukaemia (CML) is currently treated with inhibitors of the CML specific oncoprotein, bcr-abl. While this strategy is initially successful, drug resistance can become a problem. Therefore, new targets need to be identified to ensure the disease can be appropriately managed. The thior...

Descripción completa

Detalles Bibliográficos
Autores principales: Clapper, Erin, Wang, Sicong, Raninga, Prahlad V., Di Trapani, Giovanna, Tonissen, Kathryn F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139888/
https://www.ncbi.nlm.nih.gov/pubmed/32138149
http://dx.doi.org/10.3390/antiox9030207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139888/
https://www.ncbi.nlm.nih.gov/pubmed/32138149
http://dx.doi.org/10.3390/antiox9030207

Ejemplares similares